Probably due to the small number of patients enrolled and the different time and lines of exposure to ALK inhibition the overall survival does not differ significantly, however it seems there is a positive trend for the experimental group; it should be also noted that the median survival had not been reached in either group and that in the experimental group there have been no deaths.
← all excerpts
Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience.
1
—
—